PD-L1 negative

pDuFLOT and pSOX are potential regimens among senior patients with resectable gastric cancer. At this moment, pDuFLOT may be globally used while pSOX should better be applied among East Asian countries. CadCAPOX, SuCAPOX, PemCAPOX and NiCAPOX are considered as potential first-line regimens among HER2-negative senior patients. CadCAPOX and SuCAPOX are probably more fit for East Asian patients currently, while NiCAPOX may be better applied among Western countries and PemCAPOX has the potential of worldwide application. SuCAPOX is a potential regimen among HER2-negative/PD-L1-positive senior patients, while PemCAPOX may also be considered. Currently, standard CAPOX or FOLFOX regimen may still be available for HER2-negative senior patients with CLDN18.2, FGFR2b or MET positivity. Meanwhile, among HER2-positive senior patients, TraCAPOX is still considered to be available. Regarding first-line maintenance treatments, RamP is a potential regimen among HER2-negative or non-specific senior patients, especially those from Western countries. As second-line regimens, FruP and RamP may be potentially available among East Asian and worldwide HER2-negative senior patients respectively, while T-DXd has the potential of global application among HER2-positive counterparts. Concerning third-line or subsequent regimens, T-DXd is potentially available among HER2-positive senior patients, especially from East Asian countries. Among HER2-negative or non-specific patients, RamIRI is a potential regimen, especially among East Asian patients, while nivolumab and regorafenib may still be available at this moment. Meanwhile, nivolumab and other parallel regimens already recommended by guidelines are still potentially available among HER2-negative/CLDN18.2-positive senior patients. As the first network meta-analysis on this topic, our conclusions may not only provide potential supplements for current guidelines, but also reveal the necessity and directions for future clinical and mechanism researches, especially because of the underpowered subgroup data and exploratory nature of regional applicability.

No molecular marker demonstrated a significant association with recurrence risk (p > 0.05), in contrast to the FIGO stage, which showed a significant correlation (p < 0.001). Although PD-L1 expression was rare, it was significantly associated with microsatellite instability, highlighting the potential of molecular classification to identify candidates for immunotherapy. However, the low frequency of PD-L1 positivity and the small sample size warrant caution in interpreting these findings, and further research is needed to confirm the clinical relevance of PD-L1 in endometrial cancer.

P1/2, N=95, Terminated, Takeda | Trial completion date: Nov 2026 --> Jun 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Jun 2025; Sponsor decision based on limited anti-cancer activity of TAK-186.

For optimal PD-L1 assessment in breast cancer, surgical specimens from primary tumors without prior therapy are preferable due to larger evaluable tumor areas. For patients requiring neoadjuvant chemotherapy or with de novo Stage IV disease, multiple biopsies of primary tumors using thick needles before treatment, with attention being paid to sampling tumor margins to account for potential immune-excluded phenotypes, are recommended.

This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.

Tumor heterogeneity indices, particularly HI and COV derived from FDG PET/CT, demonstrated stronger predictive value for PD-L1 expression than conventional metabolic parameters. These findings suggest that metabolic heterogeneity may serve as a useful noninvasive imaging biomarker for guiding immunotherapy in NSCLC.

Our findings highlight distinct mutational profiles and prognostic variants according to PD-L1 status in TNBC. ANGPTL5 and KIAA1549L variants may serve as potential prognostic markers for PD-L1-negative tumors. These results underscore the value of incorporating genomic information to refine the prognostic stratification of TNBC.

These findings support the use of ICIs with chemotherapy for TNBC, though careful monitoring of adverse effects is warranted. PROSPERO registration number:CRD42022367366.

Thus, our data support a model in which the acquisition of neoantigens by colonic epithelial cells triggers CD8 T cell-mediated immunosurveillance. This results in the elimination of PD-L1-negative neoantigen+ stem cells by effector CD8 T cells and simultaneous repair of the colon by neoantigen-negative epithelial cells to prevent immunopathology.

In first-line chemoimmunotherapy-treated PD-L1-low/negative NSCLC, baseline LIPI can be used to independently stratify PFS and OS and identify a subgroup with poor prognosis. LIPI may support risk stratification at first-line treatment initiation. Prospective studies are warranted to validate these findings and optimize personalized treatment approaches.

In patients receiving durvalumab after CRT for unresectable stage III NSCLC, lower EDRIC was associated with longer PFS. This effect was limited to patients with positive PD-L1 tumors.